Here you will find useful information about the performance of the Mitroflow® Aortic Pericardial Heart Valve, including an overview of benefits and a summary of data that appeared in the September 2008 Journal of Thoracic and Cardiovascular Surgery. We have also included links to more information about Mitroflow, as well as upcoming surgeon education opportunities.
Why is Mitroflow becoming the choice of cardiac surgeons worldwide?
- Superior hemodynamic performance in a biological valve. With the tissue mounted outside the low-profile stent, Mitroflow’s unique design allows for an unimpeded leaflet opening for maximized flow area.
- Ease of implant. Whether you choose supra-annular or intra-annular placement, Mitroflow conforms ideally to patient anatomy, reducing the risk of peri-valvular leaks, even in patients with aortic calcification.
- Proven, 21 year clinical history. Attained results demonstrate a 21 year actuarial freedom from SVD of 71.8% for patients 65 years and over and 84.4% for patients 70 years and over.
Learn More
Read more about Mitroflow's superior performance and
durability during periods of patient activity:
"Hemodynamic Characterization of the Sorin Mitroflow Pericardial Bioprosthesis at Rest and Exercise."
